Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204.SZ)
CNY 7.86
(0.51%)
CNY 7.86
(0.51%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 282.31 Million CNY | -10.5% |
| 2022 | 315.45 Million CNY | 14.19% |
| 2021 | 276.24 Million CNY | 2.81% |
| 2020 | 268.69 Million CNY | 18.27% |
| 2019 | 227.18 Million CNY | -27.72% |
| 2018 | 314.3 Million CNY | -25.01% |
| 2017 | 419.14 Million CNY | -3.05% |
| 2016 | 432.32 Million CNY | 11.69% |
| 2015 | 387.05 Million CNY | 30.09% |
| 2014 | 297.54 Million CNY | 16.47% |
| 2013 | 255.47 Million CNY | 32.96% |
| 2012 | 192.14 Million CNY | 306.05% |
| 2011 | 47.32 Million CNY | -52.03% |
| 2010 | 98.65 Million CNY | 239.79% |
| 2009 | 29.03 Million CNY | -0.73% |
| 2008 | 29.24 Million CNY | -39.5% |
| 2007 | 48.34 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 251.21 Million CNY | 11.0% |
| 2024 Q2 | 226.33 Million CNY | -19.99% |
| 2024 Q1 | 282.87 Million CNY | 0.2% |
| 2023 Q3 | 309.02 Million CNY | 1.65% |
| 2023 FY | 282.31 Million CNY | -10.5% |
| 2023 Q4 | 282.31 Million CNY | -8.64% |
| 2023 Q2 | 303.99 Million CNY | 14.61% |
| 2023 Q1 | 265.24 Million CNY | -15.92% |
| 2022 Q3 | 258.99 Million CNY | 4.22% |
| 2022 Q1 | 259.52 Million CNY | -6.05% |
| 2022 Q2 | 248.5 Million CNY | -4.24% |
| 2022 FY | 315.45 Million CNY | 14.19% |
| 2022 Q4 | 315.45 Million CNY | 21.8% |
| 2021 Q2 | 224.58 Million CNY | -12.25% |
| 2021 Q4 | 276.24 Million CNY | 20.33% |
| 2021 FY | 276.24 Million CNY | 2.81% |
| 2021 Q3 | 229.56 Million CNY | 2.22% |
| 2021 Q1 | 255.94 Million CNY | -4.75% |
| 2020 FY | 268.69 Million CNY | 18.27% |
| 2020 Q1 | 187.2 Million CNY | -17.6% |
| 2020 Q2 | 249.18 Million CNY | 33.1% |
| 2020 Q3 | 260.14 Million CNY | 4.4% |
| 2020 Q4 | 268.69 Million CNY | 3.29% |
| 2019 FY | 227.18 Million CNY | -27.72% |
| 2019 Q4 | 227.18 Million CNY | 3.26% |
| 2019 Q3 | 220.01 Million CNY | -6.09% |
| 2019 Q1 | 311.59 Million CNY | -0.86% |
| 2019 Q2 | 234.27 Million CNY | -24.81% |
| 2018 Q2 | 397.67 Million CNY | -15.62% |
| 2018 Q1 | 471.26 Million CNY | 12.44% |
| 2018 Q4 | 314.3 Million CNY | -9.24% |
| 2018 Q3 | 346.31 Million CNY | -12.91% |
| 2018 FY | 314.3 Million CNY | -25.01% |
| 2017 Q3 | 497.04 Million CNY | 12.45% |
| 2017 Q2 | 442 Million CNY | -0.65% |
| 2017 Q1 | 444.91 Million CNY | 2.91% |
| 2017 FY | 419.14 Million CNY | -3.05% |
| 2017 Q4 | 419.14 Million CNY | -15.67% |
| 2016 Q1 | 393.96 Million CNY | 1.78% |
| 2016 Q3 | 414.56 Million CNY | 13.36% |
| 2016 Q2 | 365.72 Million CNY | -7.17% |
| 2016 FY | 432.32 Million CNY | 11.69% |
| 2016 Q4 | 432.32 Million CNY | 4.28% |
| 2015 Q3 | 289.28 Million CNY | 7.85% |
| 2015 FY | 387.05 Million CNY | 30.09% |
| 2015 Q1 | 261.84 Million CNY | -12.0% |
| 2015 Q2 | 268.21 Million CNY | 2.43% |
| 2015 Q4 | 387.05 Million CNY | 33.8% |
| 2014 Q4 | 297.54 Million CNY | 4.73% |
| 2014 Q3 | 284.1 Million CNY | 1.44% |
| 2014 FY | 297.54 Million CNY | 16.47% |
| 2014 Q1 | 254.94 Million CNY | -0.21% |
| 2014 Q2 | 280.06 Million CNY | 9.85% |
| 2013 Q3 | 201.29 Million CNY | 4.93% |
| 2013 FY | 255.47 Million CNY | 32.96% |
| 2013 Q4 | 255.47 Million CNY | 26.91% |
| 2013 Q2 | 191.83 Million CNY | 15.78% |
| 2013 Q1 | 165.69 Million CNY | -13.77% |
| 2012 FY | 192.14 Million CNY | 306.05% |
| 2012 Q1 | 49.95 Million CNY | 5.56% |
| 2012 Q2 | 57.73 Million CNY | 15.57% |
| 2012 Q3 | 73.23 Million CNY | 26.86% |
| 2012 Q4 | 192.14 Million CNY | 162.36% |
| 2011 Q4 | 47.32 Million CNY | 24.7% |
| 2011 FY | 47.32 Million CNY | -52.03% |
| 2011 Q2 | 39.83 Million CNY | -65.19% |
| 2011 Q3 | 37.94 Million CNY | -4.74% |
| 2011 Q1 | 114.45 Million CNY | 16.02% |
| 2010 Q4 | 98.65 Million CNY | 3.51% |
| 2010 FY | 98.65 Million CNY | 239.79% |
| 2010 Q3 | 95.31 Million CNY | 0.0% |
| 2009 FY | 29.03 Million CNY | -0.73% |
| 2008 FY | 29.24 Million CNY | -39.5% |
| 2007 FY | 48.34 Million CNY | 0.0% |